<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>239533</rcn>
  <id>101069212</id>
  <acronym>BWAIN</acronym>
  <teaser>Widow spiders are spread worldwide, and their bite induces severe envenomation symptoms that can lead to a complex syndrome known as latrodectism and death in severe cases. The only available specific treatment consists of polyclonal antibodies derived from horse plasma...</teaser>
  <objective>Widow spiders are spread worldwide, and their bite induces severe envenomation symptoms that can lead to a complex syndrome known as latrodectism and death in severe cases. The only available specific treatment consists of polyclonal antibodies derived from horse plasma obtained by hyperimmunization with black widow spider venom. However, this process is slow, dangerous, and implies the continuous use of large domestic animals (mainly horses) in the manufacturing process. Venom unavailability is a significant supply chain bottleneck in antivenom manufacture, which imposes a very high product cost. Also, the efficacy of this horse-derived product suffers from batch-to-batch variation, resulting in variable efficacy profiles for different batches. Finally, the non-human nature of the horse-derived antibodies may provoke severe adverse immunological reactions. The high prevalence of adverse reactions severely limits its use, and antivenom use is thus reserved for only the most extreme cases, while not being administered at all to the many patients with asthma, atopy, or other allergy-related conditions. We are developing a recombinant antivenom based on a single broadly-neutralizing fully human monoclonal antibody that can neutralize the toxic effects of widow spider bites. According to WHO nomenclature, this antibody will be called Latrotoxumab, and it will be safer to administer, more efficacious, as well as cost-competitive with existing antivenoms. In this ERC PoC project, which is based on results obtained in the ERC StG project MABSTER (grant number 850974), we will explore the commercial potential of Latrotoxumab and lay the first foundation for a spin-off company (Fang Pharma) by securing in vivo PoC, securing IPR, developing a regulatory, manufacturing, and clinical trial plan, and preparing a fully-flexed business plan, incl. market, pricing, and SWOT analyses, identification of business growth opportunities (partners and investors), and exit strategy.</objective>
  <title>Black Widow Antivenom Innovation Necessity</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2022-05-01</startDate>
  <endDate>2023-10-31</endDate>
  <ecSignatureDate>2022-04-27</ecSignatureDate>
  <duration>18</duration>
  <status>CLOSED</status>
  <identifiers>
    <grantDoi>10.3030/101069212</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2023-01-22 15:29:01</sourceUpdateDate>
  <contentCreationDate readOnly="true">2022-08-05 17:04:21</contentCreationDate>
  <contentUpdateDate>2022-09-04 03:40:11</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-09-19 14:48:56</lastUpdateDate>
  <relations>
    <associations>
      <call source="corda" type="relatedMasterCall">
        <rcn>55465</rcn>
        <title>ERC-2022-POC1</title>
        <identifier>ERC-2022-POC1</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55465</rcn>
        <title>ERC-2022-POC1</title>
        <identifier>ERC-2022-POC1</identifier>
      </call>
      <organization totalCost="0" source="corda" order="1" ecContribution="150000" terminated="false" sme="false" netEcContribution="150000" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1905565</rcn>
        <id>999990655</id>
        <vatNumber>DK30060946</vatNumber>
        <legalName>DANMARKS TEKNISKE UNIVERSITET</legalName>
        <shortName>TECHNICAL UNIVERSITY OF DENMARK DTU</shortName>
        <address>
          <street>ANKER ENGELUNDS VEJ 101</street>
          <city>KONGENS LYNGBY</city>
          <postalCode>2800</postalCode>
          <country>DK</country>
          <postBox>N/A</postBox>
          <url>http://www.dtu.dk</url>
          <geolocation>55.7718649,12.5051413</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode readOnly="true">/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Københavns omegn</name>
              <rcn>223346754</rcn>
              <nutsCode>DK012</nutsCode>
              <parents>
                <region>
                  <name>Hovedstaden</name>
                  <rcn>223346792</rcn>
                  <nutsCode>DK01</nutsCode>
                  <parents>
                    <region>
                      <name>Danmark</name>
                      <rcn>223349288</rcn>
                      <nutsCode>DK0</nutsCode>
                      <parents>
                        <region>
                          <name>Denmark</name>
                          <rcn>223513128</rcn>
                          <nutsCode>DK</nutsCode>
                          <euCode>DK</euCode>
                          <isoCode>DK</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Denmark</name>
              <rcn>223513128</rcn>
              <nutsCode>DK</nutsCode>
              <euCode>DK</euCode>
              <isoCode>DK</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>706226</rcn>
        <id>HORIZON_ERC-2022-POC1</id>
        <code>ERC-2022-POC1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS1</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1054266</rcn>
        <id>101069212_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - BWAIN (Black Widow Antivenom Innovation Necessity)</title>
        <teaser>Widow spiders are spread worldwide, and their bite induces severe envenomation symptoms that can lead to a complex syndrome known as latrodectism and death in severe cases. The only available specific treatment consists of polyclonal antibodies derived from horse plasma...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2024-03-11 17:59:28</sourceUpdateDate>
        <contentUpdateDate>2024-03-13 09:52:15</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/217/707</code>
        <title>asthma</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/pneumology/asthma</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="40" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode readOnly="true">/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
